Serial Number:
76471856
Mark:
PROBIODRUG
Status:
Cancelled-Section 8
Status Date:
11-26-2010
Filing Date:
Registration Number:
2833852
Registration Date:
04-20-2004
Chemical preparations for the use in the manufacture of pharmaceuticals for the treatment of type 2 diabetes, impaired glucose tolerance, glucosuria, and disturbances of signal action at the cells of the islets of Langerhans and insulin sensitivity in the peripheral tissue in the postprandial phase of mammals, insulin resistance, metabolic acidosis, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus, diabetes mellitus type 1, lipid disorders, hyperlipidemia, metabolism-related hypertension and cardiovascular sequelae caused by hypertension in mammals, atherosclerosis and its sequelae, inflammatory bowel disease, namely, Crohn's disease and ulcerative colitis, pancreatitis, tumor metastasis, benign prostatic hypertrophy, gingivitis, osteoporosis, for the prophylaxis or treatment of skin diseases and diseases of the mucosae, autoimmune diseases and inflammatory conditions, and for the prophylaxis or treatment of psychosomatic, neuropsychiatric and depressive illness, and neurodegenerative diseases namely anxiety, depression, sleep disorders, chronic fatigue, schizophrenia, epilepsy, nutritional disorders, spasm, and chronic pain, multiple sclerosis, Alzheimer's disease, Down Syndrome, and for use in the manufacture of contraceptive drugs for scientific, medical and biological purposes, diagnostic preparations and reagents for use in scientific and medical research Pharmaceutical preparations for the treatment of non-insulin dependent diabetes mellitus (type 2), impaired glucose tolerance, glucosuria, and disturbances of signal action at the cells of the islets of Langerhans and insulin sensitivity in the peripheral tissue in the postprandial phase of mammals, insulin resistance, metabolic acidosis, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus, diabetes mellitus type 1, lipid disorders, hyperlipidemia, metabolism-related hypertension and cardiovascular sequelae caused by hypertension in mammals; pharmaceutical preparations for the treatment of atherosclerosis and its sequelae, inflammatory bowel disease, namely, Crohn's disease and ulcerative colitis, pancreatitis, tumor metastasis, benign prostatic hypertrophy, gingivitis, osteoporosis; pharmaceutical preparations for the prophylaxis or treatment of skin diseases and diseases of the mucosae, autoimmune diseases and inflammatory conditions, and for the prophylaxis or treatment of psychosomatic, neuropsychiatric and depressive illness, and neurodegenerative diseases namely, anxiety, depression, sleep disorders, chronic fatigue, schizophrenia, epilepsy, nutritional disorders, spasm, and chronic pain, multiple sclerosis, Alzheimer's disease; Veterinary preparations for the treatment of metabolic diseases, cancerous diseases, psychosomatic, neuropsychiatric, depressive and neurodegenerative diseases in livestock and domestic animals; All purpose disinfectants, diagnostic reagents for clinical or medical use; Dietary supplements, food for enteral feeding; Agrochemicals, namely fungicides, herbicides and insecticides for agricultural and domestic use surgical, medical, dental and veterinary instruments and apparatus, namely electronic monitors, recorders and analyzers for blood pressure, blood analysis, blood glucose, insulin in the blood, pH Monitors educational services, namely conducting classes, seminars, conferences and workshops in the field of human medicine, veterinary medicine, human nutrition, pet nutrition and agriculture Chemist, physicist, microbiologist, biologist and Chemical, biological and medical research in the field of drugs and genetic engineering
Mark Description:
N/A
Class:
Scientific and technological services
Type of Mark:
Trademark
Published for Opposition Date:
01-27-2004
Owner:
Mark Drawing Status:
Typed Drawing
Abandon Date:
N/A
Business Name:
ARENT FOX LLP
Correspondent Name: